Apr 16, 2026 04:06AM Morgan Stanley Starts Kalaris (KLRS) at Overweight

Mar 31, 2026 05:31PM Raymond James maintains Strong Buy on Kalaris (KLRS) following management meetings

Mar 18, 2026 05:05AM Citizens Reiterates Market Outperform Rating on Kalaris (KLRS)

Mar 17, 2026 01:30PM William Blair on Kalaris (KLRS) after positive data: 'blockbuster potential for TH103'

Mar 17, 2026 11:42AM Raymond James: 'Remain Strong Buy rated on KLRS'

Mar 17, 2026 11:11AM Kalaris (KLRS) PT Raised to $7 at Piper Sandler

Mar 9, 2026 03:12PM William Blair Reiterates Outperform Rating on Kalaris (KLRS): "we see blockbuster potential for TH103 in nAMD"

Mar 9, 2026 10:57AM Raymond James Reiterates Strong Buy Rating on Kalaris (KLRS)

Dec 23, 2025 04:42AM Chardan Capital Markets Starts Kalaris (KLRS) at Buy

Dec 18, 2025 04:34AM Kalaris (KLRS) PT Raised to $26 at Citizens on 'TH103's differentiated profile'

Nov 25, 2025 04:07AM Kalaris' (KLRS) TH103 Could Be a Meaningful Player - Citizens

Nov 24, 2025 08:00AM Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Nov 18, 2025 04:28AM Raymond James Reiterates Strong Buy Rating on Kalaris (KLRS)

Nov 12, 2025 05:01PM Kalaris Therapeutics (KLRS) Misses Q3 EPS by 64c

Nov 12, 2025 09:46AM Raymond James Defends Kalaris (KLRS) Amid 3pct Drop: 'We continue to like this set up and recommend purchase'

Nov 3, 2025 02:34AM Citizens Starts Kalaris (KLRS) at Market Outperform

Aug 13, 2025 07:13PM Kalaris Therapeutics (KLRS) Misses Q2 EPS by 61c

Jul 23, 2025 03:50AM Piper Sandler Assumes Kalaris (KLRS) at Neutral

Jul 10, 2025 07:29AM William Blair Reiterates Outperform Rating on Kalaris (KLRS)

May 7, 2025 06:20AM Leerink Partners Starts Kalaris (KLRS) at Outperform

Apr 8, 2025 07:58AM William Blair Starts Kalaris (KLRS) at Outperform

Apr 4, 2025 08:00AM Kalaris Therapeutics (KLRS) Appoints Leone Patterson as Chair of Audit Committee

Mar 18, 2025 04:22PM Kalaris Therapeutics (KLRS) Closes Merger with AlloVir